Vitamin D receptor attenuates carbon tetrachloride-induced liver fibrosis via downregulation of YAP
- PMID: 39146589
- DOI: 10.1016/j.jhazmat.2024.135480
Vitamin D receptor attenuates carbon tetrachloride-induced liver fibrosis via downregulation of YAP
Abstract
Liver fibrosis is characterized by the excessive accumulation of extracellular matrix proteins, which can lead to cirrhosis and liver cancer. Metabolic dysfunction-associated steatosis liver diseases are common causes of liver fibrosis, sharing a similar pathogenesis with carbon tetrachloride (CCl₄) exposure. This process involves the activation of hepatic stellate cells (HSCs) into myofibroblasts. However, the detailed mechanism and effective treatment strategies require further investigation. In this study, we uncovered a negative correlation between VDR expression and YAP within HSCs. Subsequently, we demonstrated that VDR exerted a downregulatory influence on YAP transcriptional activity in HSCs. Intriguingly, activation VDR effectively inhibited the culture induced activation of primary HSCs by suppressing the transcriptional activity of early YAP. Furthermore, in vivo results manifested that hepatic-specific deletion of YAP/TAZ ameliorates CCl4-induced liver fibrosis, and nullified the antifibrotic efficacy of VDR. Importantly, a YAP inhibitor rescued the exacerbation of liver fibrosis induced by hepatic-specific VDR knockout. Moreover, the combined pharmacological of VDR agonist and YAP inhibitor demonstrated a synergistic effect in diminishing CCl4-induced liver fibrosis, primary HSCs activation and hepatic injury in vivo. These effects were underpinned by their collective ability to inhibit HSC activation through AMPK activation, consequently curbing ATP synthesis and HSCs proliferation. In conclusion, our results not only revealed the inhibition of VDR on YAP-activated liver stellate cells but also identified a synergistic effect of VDR agonist and YAP inhibitor in an AMPKα-dependent manner, providing a practical foundation for integration of multi-targeted drugs in the therapy of CCl4-induced hepatic fibrosis.
Keywords: Hepatic stellate cells; Liver fibrosis; Vitamin D receptor; Yes-associated protein.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.
Similar articles
-
Leonurine Attenuates CCl4-Induced Hepatic Fibrosis in Mice via the Hippo-YAP Pathway.Drug Des Devel Ther. 2025 Jul 30;19:6553-6571. doi: 10.2147/DDDT.S518793. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40761670 Free PMC article.
-
Tudor staphylococcal nuclease (Tudor-SN) regulates activation of quiescent hepatic stellate cells.FEBS J. 2025 Jul;292(13):3545-3564. doi: 10.1111/febs.70073. Epub 2025 Mar 17. FEBS J. 2025. PMID: 40098321
-
Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co-Inhibition of TGF-β and GSK-3 Signalling.Liver Int. 2025 Jul;45(7):e70187. doi: 10.1111/liv.70187. Liver Int. 2025. PMID: 40575954 Free PMC article.
-
Novel insights on post-translational modifications of nucleic acid methylation proteins in hepatic fibrosis.Pharmacol Res. 2025 Aug;218:107825. doi: 10.1016/j.phrs.2025.107825. Epub 2025 Jun 18. Pharmacol Res. 2025. PMID: 40554038 Review.
-
Communication initiated by hepatocytes: The driver of HSC activation and liver fibrosis.Hepatol Commun. 2025 Jul 14;9(8):e0753. doi: 10.1097/HC9.0000000000000753. eCollection 2025 Aug 1. Hepatol Commun. 2025. PMID: 40658809 Free PMC article. Review.
Cited by
-
Leonurine Attenuates CCl4-Induced Hepatic Fibrosis in Mice via the Hippo-YAP Pathway.Drug Des Devel Ther. 2025 Jul 30;19:6553-6571. doi: 10.2147/DDDT.S518793. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40761670 Free PMC article.
-
Non-parenchymal cells: key targets for modulating chronic liver diseases.Front Immunol. 2025 Jun 11;16:1576739. doi: 10.3389/fimmu.2025.1576739. eCollection 2025. Front Immunol. 2025. PMID: 40568596 Free PMC article. Review.
-
Vitamin D supplementation ameliorates ductular reaction, liver inflammation and fibrosis in mice by upregulating TXNIP in ductular cells.Nat Commun. 2025 May 13;16(1):4420. doi: 10.1038/s41467-025-59724-z. Nat Commun. 2025. PMID: 40360509 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical